Loading…
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $172M | $-252M | $-285M | $-323M | -441.6% | 627.8% | -10.5% |
| 2024 | $24M | $-314M | $-319M | $-275M | -110.6% | - | 52.3% |
| 2023 | $0M | $-209M | $-209M | $-161M | -37.8% | - | 40.2% |
| 2022 | $0M | $-146M | $-149M | $-134M | -31.9% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 23.68 | 172.35 |
| Operating Revenue | - | 0 | 0 | 23.68 | 172.35 |
| Cost Of Revenue | - | 0 | 0 | 0.83 | 6.97 |
| Gross Profit | - | 0 | 0 | 22.85 | 165.38 |
| Operating Expense | - | 151.76 | 229.95 | 362.53 | 438.47 |
| Research And Development | - | 118.50 | 163.03 | 241.65 | 258.78 |
| Selling General And Administration | - | 33.26 | 66.92 | 120.88 | 179.68 |
| Total Expenses | - | 151.76 | 229.95 | 363.35 | 445.44 |
| Operating Income | - | -151.76 | -229.95 | -339.67 | -273.08 |
| Total Operating Income As Reported | - | -151.76 | -229.95 | -339.67 | -273.08 |
| EBITDA | - | -146.17 | -209.14 | -313.82 | -251.63 |
| Normalized EBITDA | - | -146.17 | -209.14 | -313.82 | -251.63 |
| EBIT | - | -146.20 | -209.15 | -313.83 | -251.64 |
| Interest Income | - | 5.87 | 21.16 | 26.09 | 22.73 |
| Interest Expense | - | 3.14 | 0.21 | 4.93 | 33.78 |
| Net Interest Income | - | 2.74 | 20.96 | 21.16 | -11.06 |
| Other Non Operating Income Expenses | - | -0.32 | -0.36 | -0.25 | -1.28 |
| Other Income Expense | - | -0.32 | -0.36 | -0.25 | -1.28 |
| Interest Income Non Operating | - | 5.87 | 21.16 | 26.09 | 22.73 |
| Interest Expense Non Operating | - | 3.14 | 0.21 | 4.93 | 33.78 |
| Net Non Operating Interest Income Expense | - | 2.74 | 20.96 | 21.16 | -11.06 |
| Pretax Income | - | -149.34 | -209.36 | -318.76 | -285.42 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -149.34 | -209.36 | -318.76 | -285.42 |
| Net Income From Continuing And Discontinued Operation | - | -149.34 | -209.36 | -318.76 | -285.42 |
| Net Income From Continuing Operation Net Minority Interest | - | -149.34 | -209.36 | -318.76 | -285.42 |
| Net Income | - | -149.34 | -209.36 | -318.76 | -285.42 |
| Net Income Common Stockholders | - | -149.34 | -209.36 | -318.76 | -285.42 |
| Net Income Including Noncontrolling Interests | - | -149.34 | -209.36 | -318.76 | -285.42 |
| Normalized Income | - | -149.34 | -209.36 | -318.76 | -285.42 |
| Diluted NI Availto Com Stockholders | - | -149.34 | -209.36 | -318.76 | -285.42 |
| Basic Average Shares | - | 60.76 | 70.37 | 85.62 | 86.63 |
| Diluted Average Shares | - | 60.76 | 70.37 | 85.62 | 86.63 |
| Reconciled Depreciation | - | 0.03 | 0.01 | 0.01 | 0.01 |
| Reconciled Cost Of Revenue | - | 0 | 0 | 0.83 | 6.97 |
| General And Administrative Expense | - | 33.26 | 66.92 | 120.88 | 179.68 |
| Other Gand A | - | 33.26 | 27.22 | 50.89 | 76.94 |
| Salaries And Wages | - | - | 39.70 | 69.98 | 102.74 |
| Otherunder Preferred Stock Dividend | 0 | 0 | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc.this co. | SNDX | $1.6B | -5.59 | 24.71 | -441.6% | -7.18 |
| Innoviva, Inc. | INVA | $1.6B | 6.03 | 1.39 | 23.1% | 3.66 |
| Fortrea Holdings Inc. | FTRE | $1.6B | - | 2.90 | -175.0% | - |
| Capricor Therapeutics, Inc. | CAPR | $1.6B | -15.41 | 5.29 | -34.4% | -13.44 |
| Tyra Biosciences, Inc. | TYRA | $1.6B |
| - |
| - |
| - |
| - |
| - |
| -13.48 |
| 6.24 |
| -46.3% |
| -11.68 |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.6B | -10.99 | 5.21 | -47.4% | -8.97 |
| agilon health, inc. | AGL | $1.6B | - | 12.54 | -308.8% | - |
| Nurix Therapeutics, Inc. | NRIX | $1.6B | - | 2.93 | -49.1% | - |
| Sonida Senior Living, Inc. | SNDA | $1.6B | -22.19 | -142770.48 | 643445.5% | 96.78 |
| Peer Median | - | -13.48 | 4.07 | -46.8% | -8.97 | |